Coverage by the news media of the benefits and risks of medications

N Engl J Med. 2000 Jun 1;342(22):1645-50. doi: 10.1056/NEJM200006013422206.


Background: The news media are an important source of information about new medical treatments, but there is concern that some coverage may be inaccurate and overly enthusiastic.

Methods: We studied coverage by U.S. news media of the benefits and risks of three medications that are used to prevent major diseases. The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease. We analyzed a systematic probability sample of 180 newspaper articles (60 for each drug) and 27 television reports that appeared between 1994 and 1998.

Results: Of the 207 stories, 83 (40 percent) did not report benefits quantitatively. Of the 124 that did, 103 (83 percent) reported relative benefits only, 3 (2 percent) absolute benefits only, and 18 (15 percent) both absolute and relative benefits. Of the 207 stories, 98 (47 percent) mentioned potential harm to patients, and only 63 (30 percent) mentioned costs. Of the 170 stories citing an expert or a scientific study, 85 (50 percent) cited at least one expert or study with a financial tie to a manufacturer of the drug that had been disclosed in the scientific literature. These ties were disclosed in only 33 (39 percent) of the 85 stories.

Conclusions: News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between study groups or experts and pharmaceutical manufacturers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alendronate / therapeutic use
  • Anticholesteremic Agents / therapeutic use
  • Aspirin / therapeutic use
  • Biomedical Research
  • Cardiovascular Diseases / prevention & control
  • Conflict of Interest
  • Cost-Benefit Analysis
  • Disclosure
  • Drug Therapy* / economics
  • Drug-Related Side Effects and Adverse Reactions
  • Fees, Pharmaceutical
  • Humans
  • Journalism, Medical*
  • Mass Media* / statistics & numerical data
  • Newspapers as Topic
  • Osteoporosis / prevention & control
  • Pravastatin / therapeutic use
  • Risk Assessment*
  • Television
  • United States


  • Anticholesteremic Agents
  • Pravastatin
  • Aspirin
  • Alendronate